Literature DB >> 26369957

Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis.

Nicholas D Peterson1, Brandon C Rosen1, Nicholas A Dillon1, Anthony D Baughn2.   

Abstract

Pyrazinamide (PZA) is a first-line antitubercular drug for which the mode of action remains unresolved. Mycobacterium tuberculosis lacks measurable susceptibility to PZA under standard laboratory growth conditions. However, susceptibility to this drug can be induced by cultivation of the bacilli in an acidified growth medium. Previous reports suggested that the active form of PZA, pyrazinoic acid (POA), operates as a proton ionophore that confers cytoplasmic acidification when M. tuberculosis is exposed to an acidic environment. In this study, we demonstrate that overexpression of the PZA-activating enzyme PncA can confer PZA susceptibility to M. tuberculosis under neutral and even alkaline growth conditions. Furthermore, we find that wild-type M. tuberculosis displays increased susceptibility to POA relative to PZA in neutral and alkaline media. Utilizing a strain of M. tuberculosis that expresses a pH-sensitive green fluorescent protein (GFP), we find that unlike the bona fide ionophores monensin and carbonyl cyanide 3-chlorophenylhydrazone, PZA and POA do not induce rapid uncoupling or cytoplasmic acidification under conditions that promote susceptibility. Thus, based on these observations, we conclude that the antitubercular action of POA is independent of environmental pH and intrabacterial acidification.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26369957      PMCID: PMC4649215          DOI: 10.1128/AAC.00967-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels.

Authors:  Ping Lu; Anna C Haagsma; Hoang Pham; Janneke J Maaskant; Selena Mol; Holger Lill; Dirk Bald
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 2.  Mechanisms of Pyrazinamide Action and Resistance.

Authors:  Ying Zhang; Wanliang Shi; Wenhong Zhang; Denis Mitchison
Journal:  Microbiol Spectr       Date:  2014-08

3.  The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice.

Authors:  L MALONE; A SCHURR; H LINDH; D McKENZIE; J S KISER; J H WILLIAMS
Journal:  Am Rev Tuberc       Date:  1952-05

4.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.

Authors:  O Zimhony; J S Cox; J T Welch; C Vilchèze; W R Jacobs
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

5.  Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli.

Authors:  Helena I M Boshoff; Xia Xu; Kapil Tahlan; Cynthia S Dowd; Kevin Pethe; Luis R Camacho; Tae-Ho Park; Chang-Soo Yun; Dirk Schnappinger; Sabine Ehrt; Kerstin J Williams; Clifton E Barry
Journal:  J Biol Chem       Date:  2008-05-19       Impact factor: 5.157

6.  [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].

Authors:  Zhi-fei Chen; Qiang Huang; Yuan-yuan Li; Ying Zhang; Yi Ren; Kai-shang Li; Zhi-jun Fu; Shun-qing Xu
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2007-05

7.  Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain.

Authors:  Jong Seok Lee; Roland Krause; Jörg Schreiber; Hans-Joachim Mollenkopf; Jane Kowall; Robert Stein; Bo-Young Jeon; Jeong-Yeon Kwak; Min-Kyong Song; Juan Pablo Patron; Sabine Jorg; Kyoungmin Roh; Sang-Nae Cho; Stefan H E Kaufmann
Journal:  Cell Host Microbe       Date:  2008-02-14       Impact factor: 21.023

8.  A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association.

Authors: 
Journal:  Br J Dis Chest       Date:  1981-04

9.  Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Jiazhen Chen; Jie Feng; Peng Cui; Shuo Zhang; Xinhua Weng; Wenhong Zhang; Ying Zhang
Journal:  Emerg Microbes Infect       Date:  2014-08-13       Impact factor: 7.163

10.  Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis.

Authors:  Crystal M Darby; Helgi I Ingólfsson; Xiuju Jiang; Chun Shen; Mingna Sun; Nan Zhao; Kristin Burns; Gang Liu; Sabine Ehrt; J David Warren; Olaf S Andersen; Olaf S Anderson; Steven J Brickner; Carl Nathan
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

View more
  30 in total

1.  Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.

Authors:  Alice L den Hertog; Sandra Menting; Richard Pfeltz; Matthew Warns; Salman H Siddiqi; Richard M Anthony
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 2.  Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

Authors:  Pooja Gopal; Gerhard Grüber; Véronique Dartois; Thomas Dick
Journal:  Trends Pharmacol Sci       Date:  2019-11-06       Impact factor: 14.819

Review 3.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

4.  Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.

Authors:  Brandon C Rosen; Nicholas A Dillon; Nicholas D Peterson; Yusuke Minato; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 5.  New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State.

Authors:  Santiago Caño-Muñiz; Richard Anthony; Stefan Niemann; Jan-Willem C Alffenaar
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

6.  Low-Molecular Pyrazine-Based DNA Binders: Physicochemical and Antimicrobial Properties.

Authors:  Paulina Mech-Warda; Artur Giełdoń; Anna Kawiak; Natalia Maciejewska; Mateusz Olszewski; Mariusz Makowski; Agnieszka Chylewska
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

7.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

8.  Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD.

Authors:  Pooja Gopal; Wilson Nartey; Priya Ragunathan; Jansy Sarathy; Firat Kaya; Michelle Yee; Claudia Setzer; Malathy Sony Subramanian Manimekalai; Véronique Dartois; Gerhard Grüber; Thomas Dick
Journal:  ACS Infect Dis       Date:  2017-10-18       Impact factor: 5.084

9.  Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.

Authors:  Yang Che; Dingyi Bo; Xiang Lin; Tong Chen; Tianfeng He; Yi Lin
Journal:  BMC Infect Dis       Date:  2021-06-25       Impact factor: 3.090

10.  A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals.

Authors:  P G Durham; E F Young; M S Braunstein; J T Welch; A J Hickey
Journal:  Int J Pharm       Date:  2016-04-26       Impact factor: 6.510

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.